| Monoclonals | EXPRESSION SYSTEMS | THERAPEUTIC FIELDS | ||
|---|---|---|---|---|
| CHO | Murine myeloma cell line | Mammalian cell line | ||
| adalimumab | + | Rheumatoid arthritis (RA) | ||
| abciximab | + | Thrombosis | ||
| alemtuzumab | + | Chronic lymphocytic leukemia | ||
| basiliximab | + | Transplantation | ||
| bevacizumab | + | Cancer | ||
| cetuximab | + | Cancer | ||
| daclizumab | + | Transplantation | ||
| efalizumab | + | Psoriasis | ||
| gemtuzumab | + | Acute myeloid leukemia | ||
| infliximab | + | RA, Crohn, Ankylosing spondylitis | ||
| natalizumab | + | Multiple sclerosis, Crohn | ||
| omalizumab | + | Asthma | ||
| palivizumab | + | Respiratory syncytial virus infection | ||
| panitumumab | + | Cancer | ||
| rituximab | + | Lymphomas, R.A. | ||
| trastuzumab | + | Cancer | Fusion proteins | |
| abatacept | + | + | R.A. | |
| alefacept | + | Psoriasis | ||
| etanercept | + | RA, Ankylosing spondylitis, Psoriasis |
